Asahi Kasei Therapeutics gets FDA approval for HOVILPRI
Asahi Kasei Therapeutics said it secured U.S. FDA approval for HOVILPRI (pritelivir) 100 mg tablets to treat drug-resistant HSV in immunocompromised adults.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.